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The pathogenic lymphocryptovirus Epstein–Barr virus (EBV) is shown to express at least 17 distinct microRNAs
(miRNAs) in latently infected cells. These are arranged in two clusters: 14 miRNAs are located in the introns of the viral
BART gene while three are located adjacent to BHRF1. The BART miRNAs are expressed at high levels in latently
infected epithelial cells and at lower, albeit detectable, levels in B cells. In contrast to the tissue-specific expression
pattern of the BART miRNAs, the BHRF1 miRNAs are found at high levels in B cells undergoing stage III latency but are
essentially undetectable in B cells or epithelial cells undergoing stage I or II latency. Induction of lytic EBV replication
was found to enhance the expression of many, but not all, of these viral miRNAs. Rhesus lymphocryptovirus, which is
separated from EBV by  13 million years of evolution, expresses at least 16 distinct miRNAs, seven of which are closely
related to EBV miRNAs. Thus, lymphocryptovirus miRNAs are under positive selection and are likely to play important
roles in the viral life cycle. Moreover, the differential regulation of EBV miRNA expression implies distinct roles during
infection of different human tissues.
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Introduction
MicroRNAs (miRNAs) are small noncoding RNAs, generally
21–24 nt in length, that can posttranscriptionally down-
regulate the expression of mRNAs bearing complementary
target sequences [1]. Over 300 miRNAs have been identiﬁed
in humans, and comparable numbers are expressed in all
metazoan eukaryotes analyzed thus far. Although relatively
few mRNA targets for speciﬁc miRNAs have been identiﬁed
in vertebrates, experiments in plants, Caenorhabditis elegans,
Drosophila, and zebra ﬁsh indicate that miRNAs play a critical
role in the appropriate regulation of gene expression during
the differentiation and development of metazoan organisms
[1–7].
miRNAs are closely related to small interfering RNAs,
approximately 22-nt-long noncoding RNAs that are gener-
ated by cleavage of double-stranded RNAs by the RNase III
enzyme Dicer [1]. In plants and in invertebrates, small
interfering RNAs generated from double-stranded RNAs
produced during viral replication have been shown to play
an important role in the innate immune response of these
organisms to viral infection by inducing an RNA interference
response speciﬁc for the infecting virus [8,9]. While it was
therefore initially proposed that a virus-induced RNA
interference response might also be important in allowing
vertebrate species to attenuate virus replication, evidence
obtained so far has not supported this hypothesis [10].
However, a number of viruses have been shown to encode
miRNAs that are believed to play a potentially critical role in
the viral life cycle in vivo. Thus, the herpesviruses Epstein–
Barr virus (EBV), Kaposi sarcoma-associated herpesvirus
(KSHV), human cytomegalovirus, and mouse herpesvirus 68
have previously been reported to encode ﬁve, eleven, nine,
and nine miRNAs, respectively [10–13]. Moreover, the
unrelated DNA tumorvirus SV40 encodes at least one miRNA
[14]. In the case of the EBV miRNA miR-BART2 and the SV40
miRNA, it has been proposed that these viral miRNAs down-
regulate the expression of a virus-encoded mRNA [11,14]. In
contrast, mRNA targets for the other viral miRNAs have yet
to be identiﬁed, although several host mRNAs have been
proposed [11,12]. It has been hypothesized that these
herpesvirus miRNAs, which are all expressed in latently
infected cells, may facilitate the viral life cycle by blocking
innate or adaptive host immune responses or by interfering
with the appropriate regulation of apoptosis, cell growth, or
DNA replication in infected cells.
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PLoS Pathogens | www.plospathogens.org March 2006 | Volume 2 | Issue 3 | e23 0236In this manuscript, we have extended this earlier work by
identifying an additional 14 miRNAs in EBV and by cloning
and characterizing 21 miRNAs encoded by the related rhesus
lymphocryptovirus (rLCV), a primate virus that is believed to
have diverged from EBV  13 million years ago [15,16]. We
show that both EBV and rLCV encode two clusters of
miRNAs, one located near the viral BHRF1 gene and a
second in the BART gene. Remarkably, several miRNAs are
highly conserved between these two evolutionarily distinct
herpesviruses, thus arguing for their importance in the viral
life cycle. We also show that the BHRF1 cluster of EBV
miRNAs is selectively expressed in EBV-infected cells under-
going a stage III latent infection, including lymphoblastoid
cell lines (LCLs) and passaged Burkitt lymphoma (BL) cells,
but is not detected in cells undergoing stage II or stage I EBV
latent infection, such as nasopharyngeal carcinoma (NPC)
cells. In contrast, the viral BART miRNA cluster is highly
expressed in NPCs and was also readily detected in an EBVþ
primary effusion lymphoma (PEL) cell line, all of which
represent EBV stage II latency, but it is barely detectable in
LCLs and in most BL cell lines. These data suggest that virally
encoded miRNAs may play distinct roles in the EBV-induced
transformation of different human target cells.
Results
Identification of 14 Novel EBV miRNAs Encoded within the
Viral BART Gene
Previously, we reported the cloning and analysis of a set of
11 miRNAs encoded by the pathogenic human herpesvirus
KSHV that are expressed in the PEL cell line BC-1, which is
latently infected by KSHV [12]. BC-1 cells are also latently
infected by a wild-type strain of EBV, and we also cloned 222
cDNAs representing EBV miRNAs, out of the 557 cDNA
clones of cellular and viral miRNAs obtained in total. These
222 EBV miRNAs consisted of 15 distinct sequences (Table 1)
that derived from 13 different predicted primary miRNA
stem-loop precursors (Figure S1). Remarkably, only one of
these 15 miRNAs was essentially identical in sequence to one
of the ﬁve EBV-encoded miRNAs previously reported by
Pfeffer et al. [11]. Speciﬁcally, miR-BART1-5p is identical to
the previously reported miR-BART1 miRNA except that it is
2 to 3 nt longer at the 39 end. This difference may be real or,
alternately, the previously reported miR-BART1 cDNA,
which was only cloned once, may have suffered a 39 deletion
during cloning. In total, these data indicate that wild-type
EBV actually encodes at least 17 different viral miRNAs.
The previous report on EBV miRNAs by Pfeffer et al. [11]
isolated and cloned miRNAs from the human BL cell line
BL41/95. BL41/95 cells are infected with the EBV B95–8
laboratory isolate that, when compared to wild-type EBV,
suffers from an approximately12-kb deletion that removes a
large part of the EBV BART gene [17,18]. As shown in Figure
1, and implied by the miRNA names listed in Table 1, all of
the novel EBV miRNAs identiﬁed in this report are derived
from a miRNA cluster located within the predicted introns of
the BART gene, as previously also proposed for miR-BART1
and miR-BART2 [11]. Moreover, miR-BART5 to miR-BART14
are all located within the region deleted in the B95–8 EBV
strain, thus explaining their lack of detection by Pfeffer et al.
Table 1. Sequence and Genomic Location of EBV miRNAs Cloned from the BC-1 Cell Line
Name Sequences 59 to 39 Length (nt) Hits Position
miR-BART3-5p AACCUAGUGUUAGUGUUGUGCU 22 34 139086:139107
miR-BART3-3p CGCACCACUAGUCACCAGGUGU 22 44 139124:139145
miR-BART4 GACCUGAUGCUGCUGGUGUGCU 22 76 139228:139249
miR-BART1-5p UCUUAGUGGAAGUGACGUGCUGU(G) 23–24 9 139351:139373
miR-BART1-3p UAGCACCGCUAUCCACUAUGUCU 23 3 139387:139409
miR-BART5 CAAGGUGAAUAUAGCUGCCCAUCG 24 17 139675:139698
miR-BART6 CGGGGAUCGGACUAGCCUUAGA 22 3 140072:140093
miR-BART7 CAUCAUAGUCCAGUGUCCAGG(G) 21–22 5 146475:146495
miR-BART8 UACGGUUUCCUAGAUUGUACAG 22 6 146772:146793
miR-BART9 UAACACUUCAUGGGUCCCGUAG 22 3 146997:147018
miR-BART10 (U)ACAUAACCAUGGAGUUGGCUGU 22–23 17 147357:147378
miR-BART11 ACGCACACCAGGCUGACUGCC 21 24 147575:147595
miR-BART12 UCCUGUGGUGUUUGGUGUGGUUU 23 11 147936:147958
miR-BART13 UGUAACUUGCCAGGGACGGCUGA 23 1 148563:148585
miR-BART14 UACCCUACGCUGCCGAUUUACA 22 2 148744:148765
Sequence variation surrounding the recovered EBV miRNAs is indicated by parentheses surrounding the variable nucleotides. miRNAs derived from a single primary miRNA stem-loop
precursor are indicated by a 5p (59 arm) or 3p (39 arm) suffix.
DOI: 10.1371/journal.ppat.0020023.t001
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Synopsis
Vertebrate cells express a large family of diverse small RNAs, called
microRNAs, that can inhibit the expression of specific target genes.
Recently, it has become apparent that several pathogenic human
viruses, and in particular herpes viruses, also encode microRNAs that
these viruses likely use to prevent infected cells and individuals from
mounting effective antiviral responses. Here, we demonstrate that
Epstein–Barr virus (EBV), which causes infectious mononucleosis and
also some cancers in humans, makes 17 different microRNAs in
infected human cells. These microRNAs are found in two clusters in
the viral genome, one of three microRNAs, the second of 14
microRNAs, that are differentially expressed in different kinds of EBV-
induced human tumors. Analysis of the closely related rhesus
lymphocryptovirus shows that seven of these EBV microRNAs have
been conserved in this simian virus across .13 million years of
divergent evolution. This argues that these microRNAs likely play an
important role in EBV replication and represents the first demon-
stration of the evolutionary conservation of viral microRNAs.[11]. In contrast, miR-BART3 and miR-BART4 are still
present in B95–8 and are in fact located within the same
predicted BART gene intron as miR-BART1 (Figure 1A), and
hence are presumably coexpressed. However, since miR-
BART1 was only cloned once [11], it seems possible that these
two viral miRNAs were simply missed due to their low
expression (see below).
EBV miRNAs Are Differentially Expressed in Latently EBV-
Infected Cells
In contrast to the single miR-BART1 cDNA obtained,
Pfeffer et al. [11] cloned several copies of three other EBV
miRNAs derived from a second, distinct miRNA cluster
adjacent to the BHRF1 gene. Speciﬁcally, these workers
cloned miR-BHRF1–1 twice, miR-BHRF1–2 ﬁfty times and
miR-BHRF1–3 twenty-three times. Using PCR analysis, we
conﬁrmed that the BHRF1 gene was intact in latently EBV-
infected BC-1 cells (unpublished data), and the reason for our
inability to clone any of the three previously reported EBV
BHRF1 miRNAs was therefore unclear. To address this issue,
we analyzed the expression of a selection of EBV miRNAs and
mRNAs in the PEL cell line BC-1; in the wild-type EBV-
infected BL cell lines Raji, MUTU, Jijoye, and Namalwa; in the
EBV strain B95–8-infected BL cell line BL41/95 (used as a
source of EBV miRNAs by Pfeffer et al. [11]); in the LCL IM-9;
in the NPC cell line C666–1; and ﬁnally in the NPC tumor
C15, which is passaged as a xenograft in nude mice [19].
BCBL-1, a PEL cell line not infected by EBV, was used as a
negative control. This analysis included several BL cell lines
that have been extensively passed in culture—i.e., Raji, Jijoye,
Namalwa, and MUTU III—all of which represent EBV stage
III latency. We also analyzed one BL cell line, MUTU I, that is
an early passage variant of MUTU III and has been shown to
be in stage I latency [20]. All these EBV-infected cell lines
contain type I EBV except for Jijoye, which is infected with a
type II EBV [21].
As noted above, miRNA analysis using RNA derived from
the latently EBV-infected cell line BC-1 resulted in the
cloning of the BART miRNAs shown in Figure 1A but failed
to identify EBV miRNAs derived from the distinct BHRF1
cluster. Consistent with this cloning result, we observed
readily detectable levels of the mature miR-BART1-3p, miR-
BART3-3p, miR-BART5, miR-BART7, miR-BART10, and
miR-BART12 miRNAs upon Northern analysis of RNA
prepared from BC-1 cells, but failed to detect either miR-
BHRF1–1 or miR-BHRF1–2 (Figure 2A, lane 2). In contrast,
Northern analysis of RNA obtained from the BL41/95 cell line
(Figure 2A, lane 4) revealed high-level expression of miR-
BHRF1–1 and miR-BHRF1–2 but little or no detectable
expression of any of the miRNAs encoded by the EBV BART
miRNA cluster. While this was predicted for miR-BART5,
BART7, BART10, and BART12, all of which are deleted in
EBV strain B95–8 (Figure 1A), it was also true for miR-
BART1-3p and miR-BART3-3p, both of which are still
Figure 1. Genomic Location of Selected EBV and rLCV miRNAs
(A) Schematic of a segment of the EBV genome, extending from 137,490 to 152,641, with EBV genes located on the antisense strand and BART mRNA
exons located on the sense strand indicated. The location of the EBV BART miRNAs identified in this report is indicated. Also shown is the extent of the
BART gene deletion found in the EBV B95–8 strain. Not shown are the three miRNAs encoded within the EBV BHRF1 miRNA cluster, which extends from
41,474 to 42,990, or the miR-BART2 miRNA, which is located 39 to the other BART miRNAs between positions 152,747 and 152,768.
(B) Schematic of a similar segment of the rLCV genome, extending from position 131,487 to 148,684, with known rLCV homologs of EBV genes
indicated. The rLCV miRNAs identified in this report are indicated and the miRNAs conserved in EBV highlighted. Although the BART gene is thought to
be conserved in this region of the rLCV genome, based on sequence analysis, the BART exons in rLCV have not been mapped. Not shown are the rLCV
miR-rL1-1 and miR-rL1-2 miRNAs, which are encoded 39 to position 35,323 and 36,709, respectively.
DOI: 10.1371/journal.ppat.0020023.g001
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detectable in BC-1 cells.
Analysis of RNA obtained from the BL, LCL, and NPC
samples, all of which are infected with wild-type EBV strains,
indicated that the LCL and the four BL cell lines largely
shared the miRNA expression pattern seen in BL41/95, while
the two NPC samples revealed an exaggerated form of the
miRNA expression pattern seen in BC-1. Speciﬁcally, very
high-level expression of all EBV miRNAs derived from the
BART miRNA cluster was observed in the NPC samples
without detectable expression of the miRNAs encoded within
the BHRF1 cluster (Figure 2A, lanes 5 and 6). Conversely, the
IM9 LCL and the BL cell lines Raji, MUTU III, and Namalwa
had readily detectable expression of miR-BHRF1–1 and miR-
BHRF1–2 (Figure 2A, lanes 3, 7, 9, and 11), yet very low to
almost undetectable expression of the viral BART miRNAs,
even though the BART gene is intact in all these cell lines. A
different miRNA expression pattern was noted in MUTU I,
which did not express readily detectable levels of any viral
miRNA, and in Jijoye, which expressed high levels of miR-
BHRF1–2, no detectable miR-BHRF1–1, and intermediate
levels of all the BART miRNAs analyzed (Figure 2A).
To extend this analysis to additional EBV-infected cell lines,
we also performed Northern analyses for miR-BART1-3p,
miR-BART3-3p, miR-BART7, miR-BART10, miR-BHRF1–1,
and BHRF1–2, using RNA derived from the BL cell lines
P3HR-1 and Daudi, the LCLs HMy2.CIR and HCC1739 BL,
and the PEL cell line JSC-1. P3HR-1 is a subclone of Jijoye
containing an EBV that has lost a segment of the viral genome
including the EBNA-2 gene but that should retain all the EBV
miRNAs [22]. While HMy2.CIR is a spontaneous LCL,
HCC1739 BL is derived by infection of B cells with the EBV
B95–8 laboratory strain, which as noted above is deleted for
miR-BART5 through miR-BART14 (Figure 1). Analysis of the
viral miRNA expression pattern showed that JSC-1 is similar
to BC-1, the other PEL cell line tested, in that it expressed the
viral BART miRNAs but did not express detectable BHRF1
miRNAs (Figure S2). The LCLs HMy2.CIR and HCC1739 BL
were similar to the IM-9 LCL in that they both expressed
readily detectable levels of miR-BHRF1–1 and BHRF1–2 but
little or no viral BART miRNAs. Daudi was similar to the other
BL cell lines examined in Figure 2, in that it expressed readily
detectable levels of the viral BHRF1–1 and BHRF1–2 miRNAs
but only low levels of the ﬁve BART miRNAs analyzed (Figure
Figure 2. Analysis of EBV miRNA and mRNA Expression in Tumor-Derived Cells
(A) Northern analysis of selected EBV miRNAs in total RNA samples derived from the indicated cell lines and tumors. The EBV uninfected PEL cell line
BCBL-1 served as a negative control and U6 RNA as a loading control.
(B) Northern analysis of BART mRNA expression. The total RNA samples analyzed here are the same ones used in (A). The probe used was specific for the
invariant exon 7 of the alternatively spliced BART miRNAs. GAPDH mRNA expression was used as a loading control. The mobility of 28S and 18S rRNA is
indicated.
(C) RT-PCR analysis using primers specific for transcripts initiating at the viral Cp, Wp, and Qp promoters. This analysis used oligo(dT)-primed cDNA
preparations. Primers specific for the cellular GAPDH mRNA were used as a control.
DOI: 10.1371/journal.ppat.0020023.g002
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shared with Jijoye the property of expressing high levels of
miR-BHRF1–2 but no detectable miR-BHRF1–1. However,
P3HR-1 differed from Jijoye, and was more similar to the
other BL cell lines examined, in that the various viral BART
miRNAs were not detectable (Figure S2).
The discordant expression of the miR-BHRF1–1 and miR-
BHRF1–2 miRNAs observed in Jijoye and its subclone P3HR-
1 was unexpected, given that these miRNAs are located close
to each another and show concordant expression in all other
EBV-infected cell lines analyzed (Figures 2A and S2). We
therefore used PCR to clone and sequence a 418-bp region
ﬂanking the miR-BHRF1–1 sequence from the EBV genome
present in Jijoye cells (Figure S3A). This analysis revealed only
two single nucleotide sequence differences, neither of which
was located in the mature miR-BHRF1–1 sequence. However,
one sequence change maps to the miR-BHRF1–1 passenger
strand and this G to C change is predicted to disrupt a G–C
basepair located within the primary miRNA hairpin, thereby
generating a 4-nt symmetrical bulge (Figure S3B). Inspection
of a wide range of vertebrate miRNA precursors failed to
identify any stems containing two symmetrical 4-nt bulges
within the miRNA duplex region (unpublished data), and we
therefore hypothesize that this 1-nt mutation is disrupting
the appropriate processing of the primary miR-BHRF1–1
transcript in Jijoye and P3HR-1 cells. Whether this mutation
is restricted to the EBV isolate present in Jijoye and P3HR-1,
or is a general characteristic of EBV type II strains, remains to
be established.
Transcriptional Origin of the EBV miRNAs
The 14 EBV miRNAs encoded within the viral BART gene
cluster are all located within the predicted introns of this
alternatively spliced gene (Figure 1A), and one would there-
fore predict that the BART miRNAs would be coordinately
expressed and that the total level of expression of the various
alternatively spliced BART mRNAs would correlate with the
expression level of the BART miRNAs. The miRNA expres-
sion data presented in Figures 2A and S2 strongly support the
hypothesis that the BART miRNAs are indeed coordinately
expressed. To examine whether BART miRNA expression
indeed correlates with BART mRNA expression, we per-
formed a Northern analysis using the same RNA samples
analyzed for miRNA expression in Figure 2A but this time
using a probe speciﬁc for the invariant exon 7 found in all
spliced BART mRNAs. As shown in Figure 2B, we indeed
observed high-level expression of BART mRNA in the NPC
cell samples (lanes 6 and 7), an intermediate level of BART
mRNA expression in Jijoye and BC-1 cells (lanes 2 and 11),
and low to almost undetectable expression in the other BL
cell lines and in the LCL tested. The BART gene has
previously been shown to give rise to several alternatively
spliced mRNA variants, with a major species at approximately
4.8 kb and a more minor species at approximately 6.2 kb [23–
25], and the data presented in Figure 2B are consistent with
this prediction. These data also conﬁrm the previous
observation [23–27] that BART mRNAs are expressed at high
levels in NPC cells and at much lower levels in most BL cells,
with Jijoye an obvious exception. More important, these data
largely conﬁrm the hypothesis that the BART mRNA
expression pattern (Figure 2B) is predictive of the expression
pattern of the entire EBV BART miRNA cluster (Figure 2A).
We do not currently understand why the BART miRNA
expression levels seen in BC-1 and Jijoye are comparable, yet
Jijoye expresses a signiﬁcantly higher level of BART mRNA
(Figure 2A and 2B), although we hypothesize that this may
reﬂect less efﬁcient miRNA processing in Jijoye cells.
Previously, Pfeffer et al. [11], who ﬁrst identiﬁed the EBV
BHRF1 miRNA cluster, proposed that these three miRNAs
might be coexpressed with mRNAs encoding the BHRF1 gene
product. However, this appears unlikely as BHRF1 is thought
to be ﬁrst expressed early during lytic replication [28,29], and
the hairpin precursor for miR-BHRF1–1 appears to be
located 59 to the cap site for the promoter that drives lytic
BHRF1 mRNA expression. An alternative hypothesis is that
the BHRF1 miRNA cluster is actually processed out of the
BamHIH intron present in the very long pre-mRNAs that
initiate at the viral Cp and Wp promoters and, when
processed, are translated to give rise to the viral EBNA
proteins. Transcription from Cp and Wp is characteristic of
type III EBV latency [29,30], while EBV-infected cells that are
undergoing stage I or II latency instead use the Qp promoter
to express EBNA1 [31,32]. Because the Qp promoter differs
from the Cp and Wp promoters in being located between the
BHRF1 and EBNA1 open reading frames, viral pre-mRNAs
initiating at Qp could not be processed to yield any of the
BHRF1 miRNAs.
To test whether expression of the BHRF1 miRNA cluster
indeed correlates with the activity of the Cp and/or Wp
promoters, we performed RT-PCR using previously described
primers [33] speciﬁc for RNAs initiating at Wp, Cp, or Qp. As
shown in Figure 2C, we saw readily detectable levels of
transcription from Cp in Namalwa, Jijoye and MUTU III, with
weaker activity in Raji and MUTU I. The Wp promoter was
active in Jijoye, Namalwa, IM-9, and BL41/95. Finally the Qp
promoter, which is characteristic of stage I or stage II latency,
was active in MUTU I, C666–1, C15, BC-1 and, less strongly, in
Raji. Therefore, these data show that the cells predicted to be
undergoing EBV stage III latency (Raji, BL41/95, IM-9, MUTU
III, Jijoye, and Namalwa) all utilize the Cp and/or Wp
promoters, while the cells predicted to be undergoing stage
I or stage II latency (MUTU I, C666–1, BC-1, and C15) all
utilize the Qp promoter to express EBNA1. The observation
that Raji is weakly positive for Qp function, while MUTU I is
weakly positive for Cp function, likely implies that these BL
cell lines are actually a mixture of cells in stage I and stage III
latency. Nevertheless, the overall conclusion from these data
is that expression of the BHRF1 miRNA cluster indeed
correlates with usage of the Cp and Wp promoters and is
therefore likely to be characteristic of stage III latency.
Expression of Several EBV miRNAs Increases during Lytic
Replication
In the case of the miRNAs encoded by the c herpesvirus
KSHV, induction of lytic viral replication fails to signiﬁcantly
enhance the level of expression of ten out of the 11 viral
miRNAs, all of which are expressed in latently infected cells
[10,12]. The exception to this generalization, miR-K10,
appears to be expressed at higher levels during lytic
replication because, unlike the other ten viral miRNAs, it
lies within a viral transcription unit that is activated by lytic
replication [10,12]. Consideration of the genomic location of
the viral EBV miRNAs suggests, in contrast, that expression of
many of these viral miRNAs is likely to increase after
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lie within the 39 untranslated region of the early lytic mRNA
encoding BHRF1 [11,28,29] and therefore would be expected
to be induced during lytic EBV replication. Moreover, recent
data demonstrate that BART mRNA expression is also
signiﬁcantly induced during lytic replication of EBV [34], so
one would predict that BART miRNA expression would
increase in parallel. It is less clear whether lytic replication
would be likely to result in increased miR-BHRF1–1
expression, as this viral miRNA appears to lie 59 to the
BHRF1 mRNA transcription start site [11].
Examination of the level of lytic EBV replication induced
by treatment of the various LCL, BL, and PEL cell lines
analyzed in Figures 2A and S2 with TPA and n-butyrate
revealed that Daudi and MUTU I were the most responsive.
Speciﬁcally, using immunoﬂuorescence to detect the EBV
Zebra protein, which is activated very early during lytic
replication [29], we observed that TPA/n-butyrate treatment
increased the number of Zebra-positive Daudi cells from
approximately 1.7% to 19.4%, while the number of Zebra-
positive MUTU I cells increased from less than 0.5% to
approximately 54% (Figure S3). Analysis of viral miRNA
expression revealed that induction of EBV lytic replication
resulted in a clear increase in the expression of the viral
miRNAs miR-BART1-3p, miR-BART3-3p, miR-BART7, miR-
BART10-3p, and miR-BHRF1–2, but did not signiﬁcantly
enhance expression of miR-BHRF1–1 (Figure 3). In the case
of miR-BHRF1–2, this increase was particularly apparent
when the level of expression of the pre-miRNA was analyzed,
although an increase in the mature miR-BHRF1–2 level was
also detected in MUTU I cells. Together these data therefore
argue that the expression level of several EBV miRNAs
increases signiﬁcantly during lytic replication, with the
apparent exception of miR-BHRF1–1.
Viral miRNAs Have Been Conserved during
Lymphocryptovirus Evolution
While between nine and 18 miRNAs are encoded by each of
the herpesviruses analyzed so far, none of these viral miRNAs
show any obvious sequence homology [10]. On the other
hand, the herpesviruses that have been analyzed, i.e., EBV,
KSHV, cytomegalovirus, and mouse herpesvirus 68, are either
from different herpesvirus genera or, in the case of mouse
herpesvirus 68, derived from a very different species.
We reasoned that if virally encoded miRNAs are indeed
important for aspects of the virus replication cycle in vivo,
then viral miRNAs should tend to be conserved during viral
evolution. To address the validity of this hypothesis, we
sought to identify miRNAs encoded by rhesus lymphocrypto-
virus (rLCV), a member of the lymphocryptovirus genus of
which EBV is the human representative. The primate LCV
genus includes members that infect every primate species
examined so far, and the sequence divergence between
different primate LCVs predicts a phylogenetic tree that
parallels that of the primate species themselves [16]. It has
therefore been proposed that primate LCVs have coevolved
with their primate host species and that EBV and rLCV
evolutionarily diverged up to 23 million years, and at least 13
million years ago [16]. Sequence analysis of rLCV shows that
this primate virus has approximately 65% overall nucleotide
homology with EBV, with structural proteins being highly
conserved, while genes expressed during EBV latent infection
are much less well conserved [15]. More important, this
analysis predicts that the EBV BHRF1 and BART genes are
both conserved in rLCV.
We performed cDNA cloning of rLCV miRNAs using RNA
derived from the latently infected rhesus B cell line 211–98
[35]. As shown in Table 2, 257 rLCV miRNA clones represent-
ing 21 distinct viral miRNA sequences were obtained. These
could be further assigned to 15 different primary miRNA
stem-loop precursors (Figure S5). One of these miRNAs, miR-
rL1-1, was derived from a region adjacent to the rLCV BHRF1
gene, while the other 20 rLCV miRNAs were derived from the
Figure 3. Induction of Lytic Replication Can Increase EBV miRNA
Expression
The EBV-infected B-cell lines Daudi and MUTU I were either cultured
under normal conditions or treated with TPA (30 ng/ml) and n-butyrate
(300 ng/ml) for 48 h. At this point cell samples were analyzed for entry
into lytic EBV replication by immunofluorescent detection of Zebra
expression (see Figure S4) or used for RNA preparation and Northern
analysis, as described in Figure 2. In the case of miR-BHRF1–2, we here
show a larger panel that also includes the approximately 59-nt pre-
miRNA precursor, as this was more readily detected than the mature
approximately 23-nt miR-BHRF1–2 miRNA.
DOI: 10.1371/journal.ppat.0020023.g003
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rLCV miRNAs are located at the same genomic position,
relative to the viral LF2, LF3, and BILF2 genes encoded on the
opposite DNA strand, as the EBV BART miRNA cluster. As
shown in Figure 4, expression of rLCV miRNAs could be
readily demonstrated in the latently rLCV infected 211–98 cell
lineaswellasinasecond,unrelated latentlyrLCVinfected cell
line, termed 309–98 [35]. All the rLCV miRNAs analyzed gave
risetoasinglebandinthisNorthernanalysisexceptmiR-rL1-1.
Sequence comparison of the EBV and rLCV miRNAs
revealed that eight miRNAs, derived from six different stem-
loop precursors, have been largely or entirely conserved
during the evolutionary divergence of rLCV and EBV,
especially in the miRNA ‘‘seed’’ region (position 2 to 8 from
the 59 end; Figure 5). Moreover, the genomic 59 to 39 order of
the EBV BART miRNAs that are conserved in rLCV is
unchanged in this distantly related primate lymphocryptovi-
rus (Figure 1). The small number of miRNA sequence changes
that are observed are generally either at the very ends of these
miRNAs, which are known to contribute only minimally to
target mRNA recognition [36], or represent C to U or G to A
changes that may imply basepairing to a G or to a U residue,
respectively (Figure 5). Other sequence changes that do imply
a real difference in basepairing, e.g., a G to C difference
between the EBV miR-BHRF1–1 and the rLCV miR-rL1-1
miRNA, may reﬂect a real difference in the mRNA target
sequence in humans versus rhesus macaques. Of particular
interest is the one nucleotide insertion seen upon compar-
ison of EBV miR-BART7 with rLCV miR-rL1-12, while all
other viral miRNA pairs show neither insertions nor
deletions (Figure 5). This may imply that the miR-rL1-12/
miR-BART7 miRNA pair targets a noncoding region, such as
an mRNA 39 untranslated region, that can readily tolerate a
1-nt deletion or insertion.
It could be argued that the sequence conservation of the
EBV and rLCV miRNAs documented in Figure 5 reﬂects the
conservation of longer stretches of viral DNA sequence.
Conversely, if this conservation is functionally important,
then closely adjacent sequences might show more extensive
sequence divergence. To examine this issue, the sequences of
the predicted primary miRNA stem-loop precursors for each
of these EBV and rLCV miRNAs were compared. Previously,
we and others have reported that these RNA stem-loops
consist of at least three distinct domains [36,37]. The central
domain consists of the approximately 22-nt mature miRNA
sequence, shown in red in Figure 6, and its complement,
termed the miRNA passenger strand, that forms part of the
approximately 22-bp miRNA duplex intermediate, but is
generally not incorporated into the RNA-induced silencing
complex, or is incorporated less efﬁciently. The terminal loop
is a large ( 10-nt) unstructured loop (although RNA folding
programs may predict a smaller loop adjacent to a short,
rather unstable stem) whose sequence appears irrelevant as
long as it maintains an open structure [37]. Finally, the base of
the stem consists of an approximately 8- to 10-bp helical
extension of the miRNA duplex that is critical for efﬁcient
nuclear processing of the primary miRNA precursor. Because
this sequence does not form part of the miRNA duplex
intermediate per se, its sequence is not important in and of
itself, although maintenance of a helical structure is required
[4,38]. The approximately 80-nt primary miRNA stem-loop
structure is in turn ﬂanked by largely nonstructured RNA
sequences that are not believed to play a sequence-speciﬁc
role in miRNA processing and expression [39]. Therefore, we
would predict that, even though the mature viral miRNA
sequences are well conserved (Figure 5), the ﬂanking basal
stem and, particularly, the terminal loop and adjacent single-
stranded RNA regions should show signiﬁcantly more
sequence variation.
In Figure 6, the RNA sequences of six predicted primary
stem-loop precursors of miRNAs that are conserved in EBV
and rLCV are compared. As may be observed, there is indeed
Table 2. Sequence and Genomic Location of rLCV miRNAs Cloned from the 211–98 Cell Line
Name Sequences 59 to 39 Length (nt) Hits Position
miR-rL1–1 UAACCUGAUCAGCCCCGGGGUU 22 5 35323:35344
miR-rL1–3 CGCACCUCGCCGUCUCUACUGCU 23 10 133156:133178
miR-rL1–4–5p ACCUAGUAAUUGUGCGGUGUU 21 1 133292:133312
miR-rL1–4–3p CACCACACGAUCCACUAGGUCU 22 2 133327:133348
miR-rL1–5–5p AACCUAGUGCCGGUGAUGUGCU 22 12 133560:133581
miR-rL1–5–3p CGCACCACUUUUCACUAGGUGU 22 1 133598:133619
miR-rL1–6–5p UUUAGUGGAAGUGACGUGCUGUG 23 1 133696:133718
miR-rL1–6–3p UAGCACCGCUAUCCACUAUGUC 22 3 133731:133752
miR-rL1–7 CGAGGUAAACAUCGGCUUACUG 22 47 133873:133894
miR-rL1–8 UAAGGUGAAUAUAGCUGCCCAUUG 24 2 134022:134045
miR-rL1–9 UCGAUGCAUGGUCCCCCCUUAGU 23 2 134344:134366
miR-rL1–10 UAGUGCGCCGGUGACCUGAUAG 22 16 141148:141169
miR-rL1–11 UGACACUCGAUAGGAUACGGGG 22 1 141384:141405
miR-rL1–12–5p AGACCAGACCAUGCACAGUGGG 22 1 141557:141578
miR-rL1–12–3p AACGGUGCAUGGACUGGCUAGA 22 16 141597:141618
miR-rL1–13 GAUCAUAGCCAGUGUCCAGGGA 22 2 141869:141890
miR-rL1–14–5p UCGGACGGUCUGGUGCGCUUGA(UG) 22–24 62 142840:142863
miR-rL1–14–3p UCGCACAUCAGGCUGAACGAC 21 45 142878:142898
miR-rL1–15 UCCUGUAGAGUAUGGGUGUGGUUU 24 17 143314:143337
miR-rL1–16–5p AGCAGGCAUGUCUUCAUUCC 20 1 143744:143763
miR-rL1–16–3p CAUGAAACACAUGGCCUGUUC(CU) 21–23 10 143778:143800
DOI: 10.1371/journal.ppat.0020023.t002
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compared to the ﬂanking basal stem and, particularly, the
terminal loop. Overall, the sequences of the six miRNA
duplex intermediates are approximately 89% conserved
between EBV and rLCV, the basal stems are approximately
84% conserved, the terminal loops are approximately 62%
conserved, while the adjacent unstructured ﬂanking sequen-
ces, extending approximately 90 nt each side of the predicted
miRNA stem-loops shown in Figure 6, are approximately 68%
conserved. This compares to an overall sequence conserva-
tion of 65% between the EBV and rLCV genomes [15]. The
statistical signiﬁcance of the observed conservation in EBV
and rLCV of the pre-miRNA stem extension, the miRNA
duplex, and the pre-miRNA terminal loop sequence was
analyzed using the paired t-test with the null hypothesis being
that these sequences are not more highly conserved than the
59 and 39 100-nt segments ﬂanking each viral pre-miRNA. In
fact, both the miRNA duplex regions and the miRNA
extended stem regions were found to be signiﬁcantly more
highly conserved from EBV to rLCV than either the terminal
loop or the ﬂanking sequences (p , 0.05).
Additional computer analysis of the rLCV genome
sequence revealed that this virus contains a sequence that is
identical at 18 out of 23 positions to the mature EBV miR-
BHRF1–2 miRNA (Figure 5). Moreover, this sequence is found
at the same relative genomic position in rLCV, i.e.,
immediately 39 to the BHRF1 open reading frame. This
candidate rLCV miRNA, termed miR-rL1-2, also forms part
of a predicted RNA hairpin that is closely similar to the RNA
hairpin predicted for the primary EBV miR-BHRF1–2
precursor (Figure S6). To test whether this candidate rLCV
miRNA is expressed in latently infected cells, we performed a
Northern analysis that conﬁrmed the expression of miR-rL1-
2 in rLCV-infected 211–98 and 309–98 cells but not in
control, uninfected cells (Figure 4). It therefore appears that
rLCV encodes an additional miRNA, missed during cDNA
cloning, that is closely similar to EBV miR-BHRF1–2. This
brings the number of distinct miRNAs conserved during the
evolutionary divergence of EBV and rLCV to at least seven.
Discussion
Lymphocryptovirus miRNA Conservation and Function
Recent reports have documented the existence of miRNAs
encoded within the genomes of several herpesviruses, includ-
Figure 4. Analysis of rLCV miRNA Expression
Northern analysis of selected rLCV miRNAs in the rLCV-infected rhesus B-
cell lines 211–98 and 309–98. The human B-cell line BJAB served as a
negative control.
DOI: 10.1371/journal.ppat.0020023.g004
Figure 5. Sequence Comparison of miRNAs That Are Evolutionarily
Conserved in EBV and rLCV and Expressed in Virus-Infected Cells
All the indicated miRNAs were cDNA cloned from infected cells except
miR-rL1-2, whose existence was predicted in silico and then confirmed
by Northern analysis (Figure 4).
DOI: 10.1371/journal.ppat.0020023.g005
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EBV miRNA Conservation and Expressioning ﬁve miRNAs in EBV, all of which are expressed in latently
infected cells [10–13]. This report extends these earlier data by
(1) documenting that wild-type EBV actually encodes at least
17 miRNAs, ( 2) showing that these viral miRNAs are derived
from two distinct miRNA clusters that are differentially
expressed in latently EBV-infected cells, and (3) showing that
several EBV miRNAs have been conserved across  13 million
years of primate lymphocryptovirus evolution.
Analysis of EBV miRNA expression has demonstrated the
existence of a three-miRNA cluster located adjacent to the
viral BHRF1 gene [11] and a second cluster of 14 miRNAs
located within the viral BART gene (Figure 1A; Table 1).
Similarly, analysis of viral miRNA expression in rLCV latently
infected cells identiﬁed at least 16 distinct miRNAs, two
encoded adjacent to the rLCV BHRF1 homolog and the other
14 in the rLCV BART gene locus (Figure 1B; Table 2). Of these,
nine miRNAs, derived from seven different precursor stem-
loops, have been largely conserved across the .13 million
years of evolution that separate these two primate lymphoc-
ryptoviruses (Figure 5) [16]. This conservation is clearly
statistically signiﬁcant, and a comparison of the similarity of
closely adjacent viral sequences—e.g., those that form the
terminal loop of the viral primary miRNA precursors—reveals
far less sequence conservation than seen in the viral miRNAs
themselves (Figure 6). So, what does this evolutionary
conservation tell us about EBV miRNA function?
One possibility raised by this high level of sequence
conservation is that some of these viral miRNAs are actually
acting as small interfering RNAs—i.e., inducing target mRNA
degradation—rather than as canonical vertebrate miRNAs—
i.e., blocking target mRNA translation. Translational inhib-
ition requires only fairly modest miRNA sequence comple-
mentarity to the mRNA target, most notably in the
approximately 8-nt ‘‘seed’’ region located near the 59 end of
themiRNA,whilemRNAcleavagerequiresextensivehomology
to the target mRNA [36,40–44]. The almost complete con-
servation of several of these viral miRNAs (Figure 5) therefore
couldargueforadegradativemechanism.Ontheotherhand,it
is also possible that each of these conserved viral miRNAs is
partially complementary to multiple cellular mRNAs and that
the observed sequence conservation is mandated by a require-
ment to maintain signiﬁcant complementarity to several
targets that are subject to translational inhibition.
The extensive conservation of these viral miRNAs suggests
that their mRNA targets are likely to be predominantly
cellular rather than viral. EBV and rLCV show signiﬁcant
sequence divergence, especially in the viral latent genes [15],
and one would predict that a putative viral mRNA target
sequence and its viral miRNA complement would coevolve
over time. This is indeed what is seen in the ﬂanking basal
stems of the viral miRNA precursors, which show more
sequence divergence between EBV and rLCV than do the
miRNAs themselves, yet retain their ability to form an RNA
duplex (Figure 6). In contrast, if the target mRNA is cellular,
and hence fairly invariant, then very little viral miRNA
sequence change could be tolerated. Moreover, with the
exception of miR-BART2, which is antisense to the EBV
BALF5 mRNA and has been proposed to regulate BALF5
expression by a degradative RNA interference mechanism
[11], none of the EBV miRNAs are, in fact, located opposite
known viral exons (Figure 1A). Rather, they are found
opposite introns or noncoding sequences.
While seven of the lymphocryptovirus miRNAs are largely
conserved in terms of both sequence and relative genomic
position in EBV and rLCV, the remaining approximately nine
miRNAs are not. We believe this is not surprising given the
short approximately 22-nt size of mature miRNAs, and given
that some sequence differences with the mRNA target can be
tolerated [36]. As a result, one might expect potentially very
rapid evolution of viral miRNAs, resulting in the selection of
Figure 6. Sequence Comparison of the Predicted Primary miRNA Stem-Loop Structures of the Indicated rLCV and EBV miRNAs
The stem-loop shown is the rLCV sequence, with the changes observed in EBV indicated. The mature miRNA sequences are shown in red. In some cases,
the miRNA precursors give rise to two mature miRNAs. A ‘‘þ’’ sign indicates an insertion.
DOI: 10.1371/journal.ppat.0020023.g006
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advantageous to the virus. More surprising, in our view, is
the fact that several of the lymphocryptovirus miRNAs have
been conserved across millions of virus replication cycles.
Differential Expression of EBV miRNAs
In addition to the functional implications suggested by the
observed evolutionary conservation of these lymphocrypto-
virus miRNAs, our analyses also provide insights into the
regulation of EBV miRNA expression. The initial report [11]
identifying the miR-BHRF1–1, BHRF1–2, and BHRF1–3
miRNAs, as well as miR-BART1 and miR-BART2, suggested
that these two BART miRNAs were derived from introns in
the BART mRNA, as indeed conﬁrmed in this report, while
the three miRNAs that form the BHRF1 miRNA cluster were
proposed to be derived from the mRNA encoding the BHRF1
open reading frame, which is actually thought to be expressed
early during replicative infection [28,29]. However, our data
show that the BHRF1 miRNA cluster is only detectably
expressed in BL and LCL samples (Raji, BL41/95, IM-9, MUTU
III, Jijoye, and Namalwa) that use the Wp and Cp promoters
characteristic of type III latency to express the EBNA genes
[29,30] (Figure 2). In contrast, no miRNAs derived from the
BHRF1 miRNA cluster were detected in samples that were
derived from cells in type II EBV latency (the NPCs C666–1
and C15 and the PEL cell lines BC-1 and JSC-1) or type I
latency (MUTU I) that use the Qp promoter to express
EBNA1 (Figure 2) [31,32]. This correlation of BHRF1 miRNA
cluster expression and Cp/Wp promoter usage suggests that
the BHRF1 miRNAs are actually processed out of the BamHI
H intron present in the very long EBNA pre-mRNAs that are
transcribed from the Cp and Wp promoters and not, at least
during latent infection, from mRNAs encoding BHRF1. We
therefore propose that expression of the EBV BHRF1 miRNA
cluster is likely to be a characteristic of type III EBV latency.
Nevertheless, the observation that miR-BHRF1–2 expression
is markedly enhanced after induction of lytic replication
(Figure 3) suggests that the BHRF1 mRNAs induced early
during productive infection can also function as a pri-miRNA
precursor [11]. The observation that the expression of most
EBV miRNAs is enhanced during lytic replication distin-
guishes EBV from KSHV, where the majority of the viral
miRNAs show at most a modest increase in expression after
induction of lytic replication [10,12].
In this report, we have documented the existence of at least
12 novel EBV miRNAs all of which, like the previously
reported miR-BART1 and miR-BART2, are located in the
predicted introns of the alternatively spliced mRNAs derived
from the EBV BART gene (Figure 1A; Table 1). We present
data arguing that the various BART miRNAs are therefore
coordinately expressed and that their abundance is largely
predicted by the level of expression of the BART mRNAs
(Figure 2). The BART mRNAs were ﬁrst identiﬁed and shown
to be readily detectable in NPC samples but not in EBV-
infected lymphoid cell lines, although subsequent studies
identiﬁed the spliced BART mRNAs by RT-PCR in most
samples analyzed [18,23,26,27,45,46]. However, the data
presented here reveal that the BART miRNAs are only readily
detected in samples that express signiﬁcant levels of BART
mRNAs as determined by Northern blotting, including the
C666 and C15 NPC samples and B cell lines BC-1 and Jijoye.
We note, however, that low levels of the BART miRNAs can be
detected in essentially all the cell lines analyzed upon
prolonged exposure (unpublished data and [11]). Therefore,
while the NPC samples clearly express higher levels of both
the BART mRNAs and miRNAs than any of the EBV-infected
B cells, EBV-infected B cells do appear to express low but
detectable levels of both. Overall, these data therefore
indicate that expression of the BART miRNA cluster is also
characteristic of latent EBV infection and suggest that the
BART miRNAs, like the BART mRNAs, may be preferentially
expressed in EBV-infected epithelial cells and hence may play
a particularly important role during EBV infection of this
differentiated cell type. In this context, it is interesting to
note that while the EBV BART gene is clearly dispensable for
transformation of B lymphocytes in vitro [47], a region of the
EBV genome that includes the BART gene, but excludes
known EBV transforming genes such as LMP1, has been
reported to immortalize primate epithelial cells in culture
[48]. It remains to be established whether the miRNAs
encoded within the BART miRNAs cluster play a role in
epithelial cell transformation by EBV.
Materials and Methods
Cell culture, tumors, and RNA preparation. The various PEL, BL,
and LCL cell lines analyzed in this report [12,20,21,49,50] were
maintained in RPMI 1640 supplemented with 10% or 20% fetal
bovine serum, glutamine, and antibiotics. Where necessary, TPA
(Sigma, St. Louis, Missouri, United States; ﬁnal concentration 30 ng/
ml) and n-butyrate (300 ng/ml) were added for 48 h prior to RNA
preparation. The C15 nasopharyngeal tumor was passaged in nude
mice as a xenograft as described previously [19]. The rLCV latently
infected rhesus macaque cell lines 211–98 and 309–98 [35] were
maintained in RPMI containing 20% fetal bovine serum, 2 mM
glutamine, antibiotics, and 10 mM Hepes. The 211–98 cells latently
coinfected with rhesus rhadinovirus (RRV) were maintained similarly
and were used as a source of RNA for miRNA cloning. All total RNA
samples were prepared using TRIzol reagent (Invitrogen, Carlsblad,
California, United States). No difference in the pattern of rLCV
miRNA expression was detected in 211–98 cells coinfected with RRV,
and no RRV-speciﬁc miRNAs were cloned from the coinfected cells
(unpublished data). The cloning and sequencing of cDNA copies of
small RNA species derived from BC-1 cells dually infected with KSHV
and EBV, or from 211–98 cells dually infected with rLCV and RRV,
was performed as previously described [12,51] using 750 lg of total
RNA as starting material. Sequence coordinates for viral miRNAs are
given relative to the full-length type I EBV genome sequence or rLCV
sequence (see Accession Numbers section).
Northern blots and RT-PCR analyses. Northern blots and RT-PCR
analyses were conducted as previously described [52]. Brieﬂy, 30 lgo f
total RNA per sample was used in the miRNA Northern analyses. The
speciﬁc probe for each miRNA was a 32p-end-labeled full-length
antisense DNA oligonucleotide. The probe used for the U6 RNA
Northern analysis has been described [12]. For the Northern analysis
of BART mRNA expression, 10 lg of total RNA per sample was used.
A synthetic DNA oligonucleotide antisense to part of BART exon 7.
(59-AGACCCGCGCCTCTACATCACCTCTGTGCCCTGCTGGCGCTG
TGTGGGCGA GCTGATGGTTCTGCCCAACCACGGCAA-39) wasusedas
the speciﬁc probe for BART mRNA expression. The same blot wasstripped
a n dh y b r i d i z e dw i t haG A P D Hm R N A - s p e c i ﬁ cc D N Ap r o b e[ 5 2 ] .
cDNAs were prepared using RNA samples isolated from each cell
line, as previously described [52], using oligo(dT) primers. RT-PCR
analyses were performed as described previously [52], using 25 cycles
for the GAPDH primers and 40 cycles for the EBV primers. The
primers used for detection of GAPDH mRNA [52] and for
transcripts initiating at the Cp, Wp, or Qp EBV promoters have
been described [33].
Supporting Information
Figure S1. Predicted Primary miRNA Stem-Loop Structures for the
Indicated EBV miRNAs Cloned in This Report
The mature miRNAs are indicated in red. RNA folding was
performed using MFOLD.
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Figure S2. Northern Analysis of EBV miRNA Expression
This analysis was performed as described in Figure 2, using total RNA
samples derived from the indicated EBV-infected cell lines. U6 was
used as a loading control. In the case of miR-BHRF1–2, we present a
larger panel that shows both the mature 23-nt miRNA and the
approximately 59-nt pre-miRNA.
Found at DOI: 10.1371/journal.ppat.0020023.sg002 (1.5 MB TIF).
Figure S3. A Single Nucleotide Mutation May Disrupt miR-BHRF1–1
Processing in Jijoye Cells
(A) Sequence comparison of the genomic region ﬂanking the mature
miR-BHRF1–1 sequence in the type II EBV present in Jijoye cells with
the wild-type type I EBV sequence [18]. Two single nucleotide
changes and the mature miR-BHRF1–1 sequences are highlighted in
blue.
(B) One of these single nucleotide changes is predicted to disrupt the
base-pairing of the stem of the primary miR-BHRF1–1 precursor, as
indicated.
Found at DOI: 10.1371/journal.ppat.0020023.sg003 (5.8 MB TIF).
Figure S4. Immunoﬂuorescent Detection of the EBV Zebra Protein
Daudi and MUTU I cells were either cultured as normal or induced
with TPA (30 ng/ml ﬁnal concentration) and n-butyrate (300 ng/ml
ﬁnal concentration) for 48 h. At this stage, the cells were either
used for RNA analysis (see Figure 3) or ﬁxed and stained using a
mouse monoclonal anti-Zebra antibody (Argene Inc., North
Massapequa, New York, United States) followed by a TRITC-
conjugated donkey antimouse secondary antibody. Cells were also
stained with DAPI. In each case, we show a phase image (upper left),
DAPI ﬂuorescence (upper right), TRITC ﬂuorescence (lower left),
and superimposed DAPI and TRITC ﬂuorescence (lower right).
Quantitation of the number of TRITC-positive cells showed that
uninduced Daudi were approximately 1.7% Zebra-positive, induced
Daudi approximately 19.4% Zebra-positive, uninduced MUTU I less
than 0.5% Zebra-positive, and induced MUTU I approximately 54%
Zebra-positive.
Found at DOI: 10.1371/journal.ppat.0020023.sg004 (5.7 MB TIF).
Figure S5. Predicted Primary miRNA Stem-Loop Structures for the
Indicated rLCV miRNAs
Mature viral miRNAs are indicated in red.
Found at DOI: 10.1371/journal.ppat.0020023.sg005 (6.3 MB TIF).
Figure S6. Sequence Comparison of miR-BHRF1–2 miRNA and miR-
rL1-2
Differences between the predicted miR-BHRF1–2 pri-miRNA stem-
loop structure shown, and the predicted miR-rL1–2 sequence, are
indicated. This rLCV miRNA is encoded 39 to the rLCV BHRF1 open
reading frame, i.e., in the same genomic location as miR-BHRF1–2.
Although it was not recovered during cDNA cloning (Table 2), it is
detectable in rLCV-infected cells by Northern blot (Figure 4).
Found at DOI: 10.1371/journal.ppat.0020023.sg006 (493 KB TIF).
Accession Numbers
Accession numbers for the EBV genome sequence (AJ507799) and for
the rLCV sequence (AY037858) are found at GenBank (http://www.
ncbi.nlm.nih.gov/Genbank). The sequences of the novel EBV and
rLCV miRNAs and pre-miRNAs described in this report have been
deposited in miRBase (http://microrna.sanger.ac.uk/sequences/index.
shtml). The EBV miRNAs miR-BART3 to miR-BART14 have been
assigned accession numbers MI0003725 through MI0003736. The
rLCV miRNAs miR-rL1-1 to miR-rL1-16 have been assigned
accession numbers MI0003737 to MI0003752.
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